Author + information
Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller ER 3rd, Polonsky T, Thompson-Paul AM, Vupputuri S
Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
J Am Coll Cardiol 2018;71:2176–98.
1. On page 2177, in the Table of Contents, the entry “AMBP indicates ambulatory blood pressure monitoring; BP, blood pressure; and PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses” has been deleted.
2. On page 2181, in the legend to Figure 1, the abbreviation “AMBP” has been updated to read, “ABPM.”
3. On page 2185, in “PART 2: TARGETS FOR BLOOD PRESSURE LOWERING DURING ANTIHYPERTENSIVE THERAPY IN ADULTS”, “Data Synthesis and Analysis”, the third sentence in the second paragraph previously read, “In prior guidelines, there was insufficient evidence to demonstrate benefit of a BP goal <140/90 mm Hg (80).” It has been updated to read, “In prior guidelines, there was insufficient evidence to demonstrate benefit of a BP goal <140/90 mm Hg (73).
4. On pages 2187 and 2190, in Figures 2 and 3, the definition of PRISMA has been moved to the legend below the figures.
5. On page 2194, in the “Presidents and Staff” section for the American College of Cardiology, MaryAnne Elma, MPH, Senior Director, Science, Education, Quality, and Publishing” has been added.
6. On page 2197, in the Appendix 1 footnotes, the first paragraph has been updated to read,
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.
According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.
7. On page 2197, in Appendix 1, for Dr. Polonsky, column 7 “Institutional, Organizational or Other Financial Benefit” read, “None”. It has been updated to read, “AstraZeneca‡.”
8. On page 2197, in Appendix 1, in the dagger footnote, fifth sentence, “Tamar Polonsky” has been removed.
9. On page 2197, in Appendix 1, a new footnote has been added. It reads, “‡On March 1, 2018 (after publication of this Systematic Review), Dr. Polonsky, after having reviewed her listing on the CMS Open Payments Data website, realized that she had been a local PI in the STRENGTH trial, supported by AstraZeneca, and promptly reported this to the Task Force. Only one patient was recruited and Dr. Polansky did not receive any direct salary support, but by ACC/AHA standards, this would constitute a relationship with industry (RWI) and thus, in the interest of full transparency, this footnote has been added.”
© 2018 American College of Cardiology Foundation.
- 2018 American College of Cardiology Foundation